By Sydney Kodatsky | Friday, September 30, 2022 - 7:03am
The province of BC has started their review of caplacizumab - our only immediate defence against the potentially life-altering blood clots that characterize a TTP crisis.
If YOU ARE A BC RESIDENT IT IS YOUR TIME TO ACT. This life saving drug has been rejected for reimbursement in the past. To help enable access to TTP patients in BC, it is time to give input if you have TTP, or are an eligible caregiver for someone with TTP.
Remember, there are no wrong answers. You are asked for your patient perspective. Please read through the key messages document previously prepared for our meetings with MLA/MPPs that clearly identifys the need for access to caplacizumab.
Please click here to provide your patient input to BC Pharmacare. Your access to this life-saving drug depends on your willingness to contribute to the decision making process. Deadline is Oct 26 at midnight.
As a national patient organization, Answering TTP will also provide feedback as we have done in the past.
Caplacizumab was approved by Health Canada in 2020, but is not funded for use in Canada despite being a standard of care in peer nations. For more information about our advocacy for this life-saving treatment click here.